Zanzalintinib after Pluvicto for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new oral drug, zanzalintinib, for men with advanced prostate cancer that has stopped responding to hormone therapy and who have already been treated with Pluvicto. The goal is to see if this drug can slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to hormone therapy).
- You have already received at least one dose of Pluvicto (a targeted radiation therapy).
- You have not had chemotherapy for your metastatic prostate cancer (but you may have had it earlier).
- Your kidneys, liver, and blood counts are within acceptable ranges.
- You have not had other cancers recently (except for simple skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has grown after at least one prior treatment. The drug may help shrink tumors or slow their growth.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial is testing a new drug (zanzalintinib) alone or with pembrolizumab to see if it can stop cancer from coming back in people with colorectal cancer who have no visible cancer on scans but still have tumor DNA in their blood.
This trial tests a new oral medication called zanzalintinib for adults with a rare type of tumor called pheochromocytoma or paraganglioma that has spread or cannot be removed with surgery. The goal is to see if this drug can slow or stop the tumor from growing, and to evaluate its safety.
Hear when a new mCRPC (Metastatic Castration-resistant Prostate Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.